Research
Hormonal
GLP-1 receptor agonists improve liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing liver fat content, liver stiffness, and liver enzymes (ALT, AST).
If you have fatty liver disease (MASLD) along with diabetes or obesity, GLP-1 medications can help reduce fat in your liver, lower liver enzymes, and improve liver stiffness, potentially slowing or reversing liver damage.
GoodSupportsHIGH confidence
A systematic review and meta-analysis of eight studies including 2413 patients with MASLD/MASH treated with semaglutide revealed that this therapy was associated with a decrease in serum alanine transaminase (ALT)... and aspartate transaminase (AST)... levels as well as significant amelioration of liver fat content (LFC)... and liver stiffness
Why this rating
Based on systematic reviews and meta-analyses of multiple studies.
Source
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
Andrej Janež et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01615-5
narrative_reviewCited 39×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Treatment with GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produces substantial body weight loss (exceeding 15%) and improves glucose control, leading to type 2 diabetes prevention and possible disease remission.Strong
- GLP-1 receptor agonists improve cardiovascular outcomes by reducing major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, in patients with type 2 diabetes and established cardiovascular disease.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →